Aims: In the time of COVID-19, predictive molecular pathology laboratories must still timely select oncological patients for targeted treatments. However, the need to respect social distancing measures may delay results generated by laboratory-developed tests based on sequential steps a long hands-on time. Laboratory workflows should now be simplified.
Methods: The organisation of the University of Naples Federico II predictive pathology laboratory was assessed before (March-April 2019) and during (March-April 2020) the Italian lockdown.
Results: The number of patients undergoing single or multiple biomarker testing was similar in 2019 (n=43) and in 2020 (n=45). Considering adequate samples for molecular testing, before the outbreak, next-generation sequencing was mostly used (35/42, 83.3%). Testing six genes had a reagent cost of €98/patient. Conversely, in 2020, almost all cases (38/41, 92.7%) were analysed by automated testing. This latter had for any single assay/gene a significant reagent cost (€95-€136) and a faster mean turnaround time (5.3 vs 7.9 working days).
Conclusion: In the times of coronavirus, laboratory fully automated platforms simplify predictive molecular testing. Laboratory staff may be more safely and cost-effectively managed.
Keywords: laboratory personnel; medical oncology; pathology, molecular.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: UM reports personal fees (as speaker bureau or advisor) from Boehringer Ingelheim, AstraZeneca, Roche, MSD, Amgen, Merck and BMS. GT reports personal fees (as speaker bureau or advisor) from Roche, MSD and Pfizer.
Cytology in the time of coronavirus disease (covid-19): an Italian perspective.J Clin Pathol. 2020 Apr 20:jclinpath-2020-206614. doi: 10.1136/jclinpath-2020-206614. Online ahead of print. J Clin Pathol. 2020. PMID: 32312717 Free PMC article.
Severe acute respiratory syndrome coronavirus 2 is penetrating to dementia research.Curr Neurovasc Res. 2020 May 22. doi: 10.2174/1567202617666200522220509. Online ahead of print. Curr Neurovasc Res. 2020. PMID: 32442082
Nepal's Response to Contain COVID-19 Infection.J Nepal Health Res Counc. 2020 Apr 20;18(1):128-134. doi: 10.33314/jnhrc.v18i1.2608. J Nepal Health Res Counc. 2020. PMID: 32335608
Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India.Sci Total Environ. 2020 Apr 23;728:138914. doi: 10.1016/j.scitotenv.2020.138914. Online ahead of print. Sci Total Environ. 2020. PMID: 32339832 Free PMC article. Review.
Radiotherapy workflow and protection procedures during the Coronavirus Disease 2019 (COVID-19) outbreak: Experience of the Hubei Cancer Hospital in Wuhan, China.Radiother Oncol. 2020 Mar 30;148:203-210. doi: 10.1016/j.radonc.2020.03.029. Online ahead of print. Radiother Oncol. 2020. PMID: 32342870 Free PMC article. Review.
- World Health Organization (WHO) WHO Director-General's opening remarks at the media briefing on COVID-19 - 11, 2020. Available: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-COVID-19-11-march-2020
- World Health Organization (WHO) Coronavirus disease (COVID‐2019) situation reports, 2020. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports [Accessed 21 Apr 2020].
- Government of Italy Decree of the President of the Council of ministers March 9th, 2020. Available: https://www.gazzettaufficiale.it/eli/id/2020/03/09/20A01558/sg